Not in the way people want. Most people asking for the “best” drug are really asking a lazy question. They usually mean one of four things: which drug helps lose the most weight, which one is easiest to take, which one causes the fewest side effects, or which one costs the least. Those are not … Read more
The biggest change is simple: pills are no longer a side story. In the US, Eli Lilly’s Foundayo, the brand name for orforglipron, was approved by the FDA on April 1, 2026 as a GLP-1 pill for chronic weight management. Reuters also reported that Novo Nordisk had already launched an oral Wegovy option earlier in … Read more
India’s obesity-drug price war is no longer a future story. It is happening now. Reuters reported on March 31 that Novo Nordisk cut prices for Ozempic and Wegovy in India again, after the patent on semaglutide expired on March 20, 2026, opening the market to cheaper local generics. That matters because India is one of … Read more